Anti-tumor activity of KRAS(G12C) inhibitors is enhanced when combined with Cdc42 effector p21-activated kinase 4 targeting agents
Husain Yar Khan,Sahar Bannoura,Hirva Mamdani,Amro Aboukameel,Yousef Mzannar,Yiwei Li,Mohammad Najeeb Al-Hallak,Ibrahim Azar,Steve Kim,Rafic Beydoun,Ramzi Mohammad,Yosef Landesman,Yue Zhang,Erkan Baloglu,William Senapedis,Ammar Sukari,Misako Nagasaka,Anthony Shields,Asfar S. Azmi CANCER RESEARCH（2022）
AI 理解论文
溯源树
样例
